RELAPSE IN OPIOID USE DISORDER- IMPLICATIONS FOR HEALTH CARE UTILIZATION AND COSTS
Author(s)
Brady B1, Tkacz J1, Nadipelli V2, Volpicelli J3, Ronquest N2, Un H4, Ruetsch C1
1Health Analytics, Columbia, MD, USA, 2Indivior, Richmond, VA, USA, 3Institute of Addiction Medicine, Plymouth Meeting, PA, USA, 4Aetna, Blue Bell, PA, USA
OBJECTIVES: Treatment for opioid use disorder (OUD) imposes a substantial burden on the healthcare system. Non-adherence and misuse of buprenorphine medication assisted therapy (B-MAT) further augment costs while simultaneously reducing the benefit of treatment. This study estimated the impact of relapse on healthcare service utilization and costs. METHODS: Administrative claims for members with a diagnosis of opioid dependence (ICD-9 304.0 and 304.7), abuse (305.5), or poisoning (965.0) were provided by Aetna (Blue Bell, PA) from Q1 2012 through Q1 2015. Newly initiating B-MAT members were identified and examined in the 12-month period following initiation for relapse indicators, service utilization, and expenditure. Relapse was defined as the appearance of one of four proxies: ER, IP, or detoxification claim with an OUD diagnosis, change in OUD diagnosis sub-classification from “in remission” to “continuous” or “episodic”, presence of any opioid fill in the absence of trauma or surgery, an opioid prescription claim(s) covering ≥ 30 consecutive days, and abrupt discontinuation of B-MAT indicative of improper tapering. RESULTS: Overall, 60.4% of the sample exhibited at least one relapse event. Abrupt discontinuation of B-MAT, opioid use without surgery, and hospitalization were the most common relapse proxies observed. Compared to non-relapsing members, relapsing members exhibited significantly increased utilization for all services, except for pharmacy, and incurred 2.5 fold higher total healthcare costs (ps < 0.05). Inpatient hospitalization, which made up 36% of relapsing member’s costs, was the largest cost driver, at 27 times that of the non-relapsing group (p < 0.01). Outpatient hospital and ER utilization were also significantly elevated compared to the non-relapsing group (ps < 0.05). CONCLUSIONS: Relapse in OUD is prevalent, costly, and can jeopardize success with B-MAT. Improved population health management within the OUD population could prevent relapse and promote positive patient outcomes, which may reduce unnecessary healthcare spend.
Conference/Value in Health Info
2016-05, ISPOR 2016, Washington DC, USA
Value in Health, Vol. 19, No. 3 (May 2016)
Code
PMH35
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Mental Health